Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol
Robert J Klaassen,
Kristin A Shimano,
Rachael F Grace,
Jenny M Despotovic,
Ellis J Neufeld,
Carolyn M Bennett,
Clement Ma,
Wendy B London,
Cindy Neunert
Affiliations
Robert J Klaassen
Children`s Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Kristin A Shimano
UCSF Benioff Children`s Hospital, San Francisco, California, USA
Rachael F Grace
Dana-Farber/Boston Children`s Cancer and Blood Disorders Center, Boston, Massachusetts, USA
Jenny M Despotovic
Texas Children`s Hospital, Houston, Texas, USA
Ellis J Neufeld
St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
Carolyn M Bennett
Pediatrics, Emory University, Atlanta, Georgia, USA
Clement Ma
Dana-Farber/Boston Children`s Cancer and Blood Disorders Center, Boston, Massachusetts, USA
Wendy B London
Dana-Farber/Boston Children`s Cancer and Blood Disorders Center, Boston, Massachusetts, USA
Cindy Neunert
Pediatrics, Columbia University Medical School, New York, New York, USA